As the rare disease drug development landscape continues to evolve, Quoin (NASDAQ: QNRX) is focused on staying ahead of its competitors.
New York, New York–(Newsfile Corp. – June 14, 2022) – PCG Digital — The life sciences industry has always been dynamic; a collective of organizations from small and agile to large multinationals with one common feature, a need to be creative enough to adapt and change course as challenges arise. Social, political and economic influences, the regulatory environment and competition from deep-pocketed Big Pharma all present substantial challenges for small biotech companies. The overarching question is: how do smaller biotech and biopharma companies achieve success while navigating these often complicated external pressures?
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/127600